Protein Expression in Samples From Young Patients With Rhabdomyosarcoma

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: August 31, 2011
Last updated: May 8, 2015
Last verified: May 2015

RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies protein expression in samples from young patients with rhabdomyosarcoma.

Condition Intervention
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Evaluating Candidate Protein Expression in Human Rhabdomyosarcoma (RMS)

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • RMS protein expression profile [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Tumor tissue

Estimated Enrollment: 77
Study Start Date: November 2011
Estimated Primary Completion Date: January 2100 (Final data collection date for primary outcome measure)
Detailed Description:


  • To measure the protein expression of candidate proteins in human rhabdomyosarcoma (RMS) tumor samples.

OUTLINE: Archived tumor tissue samples are analyzed for protein expression (i.e., Notch1, Hey1, FGFR4, and Sp1) by IHC techniques and standard commercially available antibodies. Candidate proteins are then correlated with each patient age, gender, rhabdomyosarcoma (RMS) tumor stage, and RMS tumor subtype.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Children with rhabdomyosarcoma (RMS) enrolled in the Children's Oncology Group clinical trials



  • Tumor tissue samples from children with rhabdomyosarcoma (RMS) enrolled in the Children's Oncology Group clinical trials

    • Alveolar rhabdomyosarcoma (ARMS)
    • Embryonal rhabdomyosarcoma (ERMS)


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01426945

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Corinne M. Linardic, MD, PhD Duke Cancer Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Children's Oncology Group Identifier: NCT01426945     History of Changes
Other Study ID Numbers: ARST11B3, COG-ARST11B3, ARST11B3, NCI-2011-03534
Study First Received: August 31, 2011
Last Updated: May 8, 2015
Health Authority: United States: Federal Government

Keywords provided by Children's Oncology Group:
alveolar childhood rhabdomyosarcoma
previously treated childhood rhabdomyosarcoma
previously untreated childhood rhabdomyosarcoma
recurrent childhood rhabdomyosarcoma
embryonal childhood rhabdomyosarcoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Sarcoma processed this record on October 13, 2015